Kangmei Pharmaceuticals lost 1.4 billion yuan in half a year, the investment in the hospital miserable!

Medical network September 7th, half a year loss of 1.4 billion! Kangmei Pharmaceuticals to change owners, the hospital to do? On September 3rd, because of the "fake 30 billion" ST Kangmei re-branding, and just the day before, Kangmei Pharmaceuticals issued an announcement that its controlling shareholders and actual controllers intend to change to Yilin Investment, the background of state-owned.
means that Comey Pharmaceuticals is going to change owners.
good news, ST Kangmei closed for two consecutive working days, the current market value of 16.2 billion.
, it is understood that before the storm, the total market value of Comey Pharmaceuticals had reached more than 130 billion yuan.
just a few days ago, Kangmei Pharmaceuticals released its first half 2020 report, announcing that the company achieved revenue of 2.517 billion yuan, down 69.05 percent year-on-year;
, Commy Pharmaceuticals lost 1.424 billion yuan in the first half of the year.
company's semi-annual report, Kangmei continued to optimize the business structure, reduce the non-Chinese medicine business resources, focusing on the development of the main industry.
in the spin-off of non-main business, Kangmei while selling land for a living, while not yet obtaining a sales license to charge buyers subscription money.
semi-annual report revealed that Kangmei Health Industry Investment Co., Ltd. intends to sell guangzhou two state-owned construction land use rights and its above-ground and underground buildings and construction projects under construction for no more than 1.13 billion yuan.
And according to Yunnan Housing Network and other local media reports, in mid-August, Kangmei Kunming Health City was submitted to the Gong District Housing and Construction Bureau name notice, because the project without a sales license has been charged to buyers subscription money.
And in the medical field, in June this year, the Beijing News shell finance reporter visited Puning to visit the home of Kangmei Pharmaceuticals found that although The Puning Kangmei Hospital, which was invested by Kangmei, had been in use for many years, most of the floors of a medical building in the hospital were idle and unrenished.
billions of dollars in market capitalisation, penalties imposed by the CSRC, and a blood-swap at the top of the executive class... Over the past year or so, The changes in Comey Pharmaceuticals have been frequent, and for hospitals that have been restructured and invested by Comey Pharmaceuticals, major changes may be inevitable.
the post-Kangmei era, where did it go to be put in hospital? According to the "look at the medical profession" understand that in recent years, as the upper reaches of the medical industry chain of pharmaceutical companies Kangmei Pharmaceuticals, the layout of the hospital's hand is very large.
According to Kangmei Pharmaceuticals' official website, the company has invested in the management of dozens of public hospitals, including Puning Kangmei Hospital, Meihekou Central Hospital, Rongchang Zhong Hospital, Kaiyuan City Center Hospital, Tonghua County People's Hospital, and hosts more than 100 public hospital pharmacies.
and many pharmaceutical companies to buy private hospitals is different, Kangmei Pharmaceuticals has a lot of money, the target is targeted at the state-owned enterprises medical groups to dare to touch the public hospital restructuring.
Its acquisition of hospital project profit model is mainly based on hospital management and supply chain management, through the collection of a certain percentage of management fees and the establishment of commercial subsidiaries to undertake hospital supply chain management to thicken performance, is the most easy to promote the public hospital restructuring model.
According to kangmei Pharmaceuticals' notice in August 2018, Kangmei Pharmaceuticals and Tongliao State-owned Capital Investment Operations Co., Ltd. and Tongliao City Hospital signed a "Medical Investment Cooperation Agreement", Kangmei Pharmaceuticals plans to invest an further 2.5 billion yuan to build a new hospital area of Kangmei Tongliao Hospital.
, this optimistic expectation was supported by a market capitalisation of hundreds of billions of dollars before Comey's financial data "exploded".
Today's financial data are ugly, for investment, custody of hospitals, the previously planned investment funds may also face a significant reduction in the risk of related hospitals or face greater financial risks, some of the hospitals restructured by Kangmei Pharmaceuticals may face a secondary restructuring situation.
Xu Weicai, deputy director of the Health and Wellness Bureau in Shanyang County, Shaanxi Province, said that some pharmaceutical companies choose to enter the hospital has some advantages, but still have disadvantages.
most important issue is that hospitals and management are often unsofessial.
Regarding the crisis of Kangmei, an industry insider told the Medical Watch Community that in the overall situation of medical reform led by the Super Health Insurance Bureau, many pharmaceutical companies lacking market competitiveness will face the dilemma of transformation, long medical investment cycle, even if not the hospital operation and management challenges, it is difficult to save some pharmaceutical companies are currently facing a crisis.
At the same time, also want to invest in the acquisition of hospitals enterprises suggest that the management of medicine can not be quick to profit, but also for hospitals, staff, patients to consider, on this basis to achieve the government, enterprises, health care, patients win-win situation.
out of capacity to make blind investments, not for the hospital's medium- and long-term healthy development considerations, the result or the embarrassing situation of multiple losses.
.